From: Relation between GSTP1 polymorphism and oxidative stress in patients with hepatocellular carcinoma
Group | Control | Patient | p value | ||
---|---|---|---|---|---|
Median | Range | Median | Range | ||
ALT (U/L) N: up to 41 | 25 | 21:30.8 | 51 | 35:67.5 | < 0.001* |
AST (U/L) N: up to 40 | 26 | 20:30 | 82 | 54:114 | < 0.001* |
ALP (U/L) N: up to 279 | 92.25 | 82:104.8 | 175 | 127:248 | < 0.001* |
ALB (g/dl) N: 3.5:5.2 | 4 | 3.9:4.2 | 3.27 | 2.8:3.5 | < 0.001* |
INR N: up to 1 | 1 | 1:1 | 1.24 | 1.1:1.3 | < 0.001* |
UREA (mg/dl) N: 15-45 | 31 | 28:36 | 28 | 22:34.5 | 0.007* |
AFP (ng/ml) N: up to 10.5 | 1.85 | 1.2:2.7 | 117 | 16.3:1559.8 | < 0.001* |
LDH (U/L) N: up to 250 | 116.5 | 102.3:130 | 207 | 172:248 | < 0.001* |
HB (gm/dl) N: Male (13:18) Female (12:16) | 12.3 | 11.1:13.4 | 13 | 12:14 | 0.001* |
TLC*10^9/L N: 4-11 | 7.3 | 5.9:8.2 | 5.3 | 4.2:6.9 | < 0.001* |
PLT*10^9/L N: 150-400 | 226.5 | 194.3:280.8 | 125 | 81:195 | < 0.001* |
GSH (mM/mg) N: 684-2525 | 2010 | 1619.8:2310.8 | 1916.5 | (862-3011) | 0.152 |